%0 Journal Article %A Yurui Gao %A Anirban Sengupta %A Muwei Li %A Zhongliang Zu %A Baxter P. Rogers %A Adam W. Anderson %A Zhaohua Ding %A John C. Gore %A for the Alzheimer’s Disease Neuroimaging Initiative %T Functional connectivity of white matter as a biomarker of cognitive decline in Alzheimer’s disease %D 2020 %R 10.1101/2020.05.05.20091892 %J medRxiv %P 2020.05.05.20091892 %X Objective In vivo functional changes in white matter during the progression of Alzheimer’s disease (AD) have not been previously reported. Our objectives are to measure changes in white matter functional connectivity (FC) in an aging population undergoing cognitive decline as AD develops, to establish their relationship to neuropsychological scores of cognitive abilities, and to assess their performance as predictors of AD.Methods Analyses were conducted using resting state functional MRI (rsfMRI) and neuropsychological data from 383 ADNI participants, including 136 cognitive normal (CN) controls, 46 with significant memory concern, 83 with early mild cognitive impairment (MCI), 37 with MCI, 46 with late MCI, and 35 with AD dementia. We used novel analyses of whole brain rsfMRI data to derive FC metrics between white matter tracts and discrete cortical volumes, as well as FC metrics between different white matter tracts, and their relationship to 6 cognitive measures. We then implemented supervised machine learning on white matter FCs to classify the participants and evaluated the performance.Results Significant decreases were found in white matter FCs with prominent, specific, regional deficits appearing in late MCI and AD dementia patients relative to CN. These changes significantly correlated with behavioral measurements of impairments in cognition and memory. The sensitivity and specificity for distinguishing AD dementia and CN using white matter FCs were 0.83 and 0.81 respectively.Conclusions and Relevance The white matter FC decreased in late MCI and AD dementia patients compared to CN participants, and the white matter FC correlates with cognitive measures. White matter FC based classification shows promise for differentiating AD patients from CN. It is suggested that white matter FC may be a novel imaging biomarker of AD progression.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe project is supported by the NIH grant R01 NS093669 and a Vanderbilt University Discovery Grant 600670. We also thank the Vanderbilt Advanced Computing Center for Research and Education (ACCRE) for the support of cluster computation. Data collection and sharing for this project was funded by the ADNI (NIH Grant U01 AG024904) and DOD ADNI (DOD award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the NIH (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe analyzed data may be available upon request. Please contact Dr. Gao for further information. %U https://www.medrxiv.org/content/medrxiv/early/2020/05/09/2020.05.05.20091892.full.pdf